Melbourne, Australia-based Telix Pharmaceuticals reported a spike in revenue for the second quarter of 2024, citing strong sales of Illuccix (gallium-68 prostate-specific membrane antigen [PSMA]-11), its PSMA-PET radiotracer kit for prostate cancer imaging.
For the second quarter (end-June 30), the company reported unaudited total revenue of 189 million Australian dollars ($126 million U.S.), an increase of 55% over the same period in 2023 and an increase of 8% over the first quarter in 2024. Revenue generated from U.S. Illuccix sales was approximately 184 million Australian dollars ($123 million U.S.), the company said.
![Pittsburgh Compound B (PiB) PET distribution volume ratio (DVR) images were projected onto fsaverage surfaces from FreeSurfer and surface smoothed, with PiB (amyloid) slope maps created using ordinary least squares regression (time as only factor) and mixed effects models for 154 participants run at each vertex (P < .01; model: longitudinal Geriatric Depression Scale score estimated by amyloid slope × time + [sex + education + age] × time). This map visualizes the results of the linear mixed-effects models (t score of the main variable, amyloid slope × time) such that regions with a greater t score (red) represent areas in which greater depressive symptoms are associated with greater amyloid accumulation (amyloid slope). Anatomical landmarks are provided: L refers to the left hemisphere, R refers to the right hemisphere, and additional labels indicate the anterior and posterior ends of the brain. Images available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of JAMA Open Network.](https://img.auntminnie.com/files/base/smg/all/image/2024/08/PET_depression.66cf997f7e441.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
